HER2 + breast cancer, which responds to targeted therapies like trastuzumab, has been identified in both species, though HER2 overexpression in CMTs appears less frequent and less well-defined than in humans (Kwon et al. 2023). This evidence concerns the gene ERBB2 and breast carcinoma.